Companies: 48,687 Total Market Cap: 127281996338110.52

Ipsen S.A.

LON-0MH6
Pharmaceutical Preparations
Rank #1860
Market Cap 9.73 B
Volume 587.60
Price 137.95
Change (%) 1.86%
Country or region France France

Ipsen S.A.'s latest marketcap:

9.73 B

As of May 4, 2025, Ipsen S.A.'s market capitalization has reached $9.73 B. According to our data, Ipsen S.A. is the 1860th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 9.73 B
Revenue (ttm) 3.92 B
Net Income (ttm) 379.42 M
Shares Out 0
EPS (ttm) 4.55
Forward PE 0.00
Ex-Dividend Date June 4, 2025
Earnings Date July 31, 2025
Market Cap Chart
Data Updated: May 4, 2025

Ipsen S.A.'s yearly market capitalization.

Ipsen S.A. has seen its market value grow from £5.03 B to £6.86 B since 2020, representing a total increase of 36.45% and an annual compound growth rate (CAGR) of 7.47%.
Date Market Cap Change (%)
April 25, 2025 £6.86 B -8.88%
December 31, 2024 £7.52 B -2.7%
December 29, 2023 £7.73 B 5.32%
December 30, 2022 £7.34 B 32.06%
December 31, 2021 £5.56 B 10.66%
December 31, 2020 £5.03 B

Company Profile

About Ipsen S.A.

Ipsen S.A. is a global biopharmaceutical company specializing in innovative treatments across oncology, neuroscience, and rare diseases. Founded in 1929 and headquartered in Boulogne-Billancourt, France, Ipsen is committed to advancing patient care through cutting-edge therapies.

Key Therapeutic Areas & Products

  • Oncology: Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik
  • Neuroscience: Dysport and other neurotoxin-based treatments
  • Rare Diseases: Bylvay, NutropinAq, Increlex, Sohonos

Pipeline Highlights

  • Phase III: Cabometyx + Atezolizumab (metastatic prostate cancer), Taverik (follicular lymphoma), Bylvay (biliary atresia), Dysport (chronic/episodic migraine)
  • Phase II: Fidrisertib (fibrodysplasia ossificans progressiva), Elafibranor (primary sclerosing cholangitis), IPN10200 (longer-acting neurotoxins)
  • Phase I: IPN60210 (relapsed/refractory multiple myeloma), IPN60260 (viral cholestatic disease)

Ipsen continues to drive innovation in biopharmaceuticals, addressing unmet medical needs with a robust pipeline and established therapies.

Frequently Asked Questions

As of May 4, 2025, Ipsen S.A. (including the parent company, if applicable) has an estimated market capitalization of $9.73 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Ipsen S.A. global market capitalization ranking is approximately 1860 as of May 4, 2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region France
Founded 1929
IPO Date n/a
Employees 5,358
CEO David Loew
Sector
Industry Pharmaceutical Preparations
Address 65, quai Georges Gorse
Boulogne-Billancourt, 92100
France
People Also Watch
LJSE-KRKG
195.97 1.86%
BUD-RICHTER
29.91 1.86%
KOSDAQ-145020
264.12 1.86%
LON-0A5J
51.70 1.86%